Anti	O
-	O
band	B-GP
3	I-GP
and	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
are	O
increased	O
in	O
Plasmodium	B-DS
vivax	I-DS
infection	I-DS
and	O
are	O
associated	O
with	O
anemia	B-DS

Clearance	O
of	O
non	O
-	O
infected	O
red	O
blood	O
cells	O
(	O
nRBCs	O
)	O
is	O
one	O
of	O
the	O
main	O
components	O
of	O
anemia	B-DS
associated	O
with	O
Plasmodium	B-DS
vivax	I-DS
malaria	I-DS
.	O

Recently	O
,	O
we	O
have	O
shown	O
that	O
anemic	O
patients	O
with	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
had	O
elevated	O
levels	O
of	O
anti	O
-	O
RBCs	O
antibodies	B-GP
,	O
which	O
could	O
enhance	O
in	O
vitro	O
phagocytosis	O
of	O
nRBCs	O
and	O
decrease	O
their	O
deformability	O
.	O

Using	O
immunoproteomics	O
,	O
here	O
we	O
characterized	O
erythrocytic	O
antigens	O
that	O
are	O
differentially	O
recognized	O
by	O
autoantibodies	B-GP
from	O
anemic	O
and	O
non	O
-	O
anemic	O
patients	O
with	O
acute	O
vivax	B-DS
malaria	I-DS
.	O

Protein	O
spots	O
exclusively	O
recognized	O
by	O
anemic	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
were	O
identified	O
by	O
mass	O
spectrometry	O
revealing	O
band	B-GP
3	I-GP
and	O
spectrin	B-GP
as	O
the	O
main	O
targets	O
.	O

To	O
confirm	O
this	O
finding	O
,	O
antibody	B-GP
responses	O
against	O
these	O
specific	O
proteins	O
were	O
assessed	O
by	O
ELISA	O
.	O

In	O
addition	O
,	O
an	O
inverse	O
association	O
between	O
hemoglobin	B-GP
and	O
anti	O
-	O
band	B-GP
3	I-GP
or	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
levels	O
was	O
found	O
.	O

Anemic	O
patients	O
had	O
higher	O
levels	O
of	O
IgG	B-GP
against	O
both	O
band	B-GP
3	I-GP
and	O
spectrin	B-GP
than	O
the	O
non	O
-	O
anemic	O
ones	O
.	O

To	O
determine	O
if	O
these	O
autoantibodies	B-GP
were	O
elicited	O
because	O
of	O
molecular	O
mimicry	O
,	O
we	O
used	O
in	O
silico	O
analysis	O
and	O
identified	O
P	B-OG
.	I-OG
vivax	I-OG
proteins	O
that	O
share	O
homology	O
with	O
human	B-OG
RBC	O
proteins	O
such	O
as	O
spectrin	B-GP
,	O
suggesting	O
that	O
infection	B-DS
drives	O
autoimmune	O
responses	O
.	O

These	O
findings	O
suggest	O
that	O
band	B-GP
3	I-GP
and	O
spectrin	B-GP
are	O
potential	O
targets	O
of	O
autoantibodies	B-GP
that	O
may	O
be	O
relevant	O
for	O
P	B-DS
.	I-DS
vivax	I-DS
malaria	I-DS
-	O
associated	O
anemia	B-DS
.	O

Introduction	O

Plasmodium	B-OG
vivax	I-OG
accounts	O
for	O
a	O
sizable	O
portion	O
of	O
the	O
global	O
malaria	B-DS
burden	O
and	O
is	O
being	O
increasingly	O
associated	O
to	O
fatal	O
outcomes	O
with	O
anemia	B-DS
as	O
one	O
of	O
the	O
major	O
complications1	O
,	O
2	O
particularly	O
in	O
young	O
children1	O
–	O
4	O
and	O
pregnant	O
women5	O
,	O
6	O
.	O

Despite	O
its	O
enormous	O
public	O
health	O
importance	O
,	O
the	O
mechanisms	O
behind	O
vivax	B-DS
malaria	I-DS
-	O
associated	O
anemia	B-DS
are	O
not	O
well	O
known	O
.	O

Malaria	B-DS
-	O
induced	O
anemia	B-DS
is	O
thought	O
to	O
arrise	O
from	O
hemolysis	O
of	O
infected	O
RBCs	O
,	O
as	O
well	O
as	O
from	O
clearance	O
of	O
nRBCs7	O
,	O
8	O
.	O

Several	O
reasons	O
have	O
been	O
suggested	O
to	O
explain	O
the	O
removal	O
of	O
nRBC8	O
,	O
including	O
impaired	O
RBC	O
production	O
through	O
dyserythropoiesis	O
or	O
bone	O
marrow	O
insufficiency9	O
,	O
exposition	O
of	O
erythrocytes	O
to	O
oxidative	O
stress	O
triggered	O
by	O
parasite	O
rupture	O
or	O
host	O
immune	O
responses10	O
,	O
11	O
,	O
and	O
mechanical	O
ex	O
vivo	O
destruction	O
of	O
non	O
-	O
infected	O
red	O
blood	O
cells	O
(	O
nRBCs	O
),	O
as	O
it	O
has	O
been	O
demonstrated	O
using	O
a	O
splenic	O
sinusoid	O
model12	O
,	O
in	O
addition	O
to	O
other	O
mechanisms	O
that	O
may	O
also	O
be	O
relevant	O
to	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
associated	O
anemia	B-DS
.	O

In	O
P	B-DS
.	I-DS
falciparum	I-DS
infections	I-DS
,	O
one	O
of	O
the	O
causes	O
underlying	O
malarial	B-DS
anemia	I-DS
is	O
the	O
augmented	O
removal	O
of	O
nRBCs	O
possibly	O
boosted	O
by	O
increased	O
levels	O
of	O
self	O
-	O
antibodies	B-GP
against	O
nRBCs	O
proteins13	O
–	O
15	O
.	O

Evidences	O
in	O
this	O
line	O
are	O
given	O
by	O
studies	O
that	O
have	O
shown	O
an	O
inverse	O
association	O
between	O
hemoglobin	B-GP
levels	O
and	O
anti	O
-	O
phosphatidylserine	O
antibodies	B-GP
in	O
humans	B-OG
with	O
late	O
post	O
-	O
anemia	B-DS
due	O
to	O
P	B-DS
.	I-DS
falciparum	I-DS
infection14	I-DS
.	O

In	O
addition	O
,	O
one	O
may	O
also	O
take	O
into	O
account	O
the	O
expansion	O
of	O
T	O
-	O
bet	O
+	O
B	O
cells	O
and	O
the	O
production	O
of	O
anti	O
-	O
erythrocyte	O
antibodies	B-GP
in	O
ex	O
vivo	O
cultures	O
of	O
naïve	O
human	B-OG
peripheral	O
blood	O
mononuclear	O
cells	O
exposed	O
to	O
P	B-OG
.	I-OG
falciparum	I-OG
-	O
infected	O
erythrocyte15	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
role	O
of	O
autoimmunoglobulins	B-GP
in	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
is	O
an	O
important	O
field	O
of	O
research	O
that	O
has	O
been	O
mainly	O
explored	O
through	O
clinical	O
studies	O
and	O
case	O
reports16	O
–	O
18	O
.	O

Our	O
group	O
recently	O
demonstrated	O
that	O
in	O
vitro	O
erythrophagocytosis	O
of	O
nRBCs	O
was	O
mediated	O
by	O
anti	O
-	O
erythrocyte	O
antibodies	B-GP
purified	O
from	O
anemic	O
patients	O
with	O
vivax	B-DS
malaria	I-DS
,	O
possibly	O
through	O
a	O
decrease	O
in	O
cell	O
deformability19	O
.	O

Thus	O
,	O
characterization	O
of	O
RBCs	O
targets	O
for	O
autoimmunoglobulins	B-GP
elicited	O
by	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
may	O
be	O
important	O
for	O
the	O
understanding	O
of	O
vivax	B-DS
malaria	I-DS
-	O
associated	O
anemia	B-DS
as	O
well	O
as	O
for	O
autoimmune	B-DS
diseases	I-DS
due	O
to	O
its	O
clinical	O
and	O
therapeutic	O
potential	O
.	O

Herein	O
we	O
used	O
two	O
different	O
strategies	O
to	O
understand	O
the	O
relationship	O
between	O
autoantibodies	B-GP
against	O
nRBCs	O
and	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
associated	O
anemia	B-DS
.	O

First	O
,	O
we	O
used	O
an	O
immunoproteomic	O
approach	O
to	O
identify	O
the	O
erythrocytic	O
antigens	O
reactive	O
to	O
IgG	B-GP
from	O
anemic	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
.	O

Then	O
,	O
we	O
confirmed	O
the	O
reactivity	O
of	O
those	O
antigens	O
using	O
ELISA	O
and	O
investigated	O
the	O
possible	O
contribution	O
of	O
molecular	O
mimicry	O
to	O
vivax	B-DS
malaria	I-DS
associated	O
-	O
anemia	B-DS
by	O
searching	O
for	O
P	B-OG
.	I-OG
vivax	I-OG
proteins	O
that	O
share	O
homology	O
with	O
human	B-OG
RBCs	O
.	O

Results	O

Differential	O
RBC	O
protein	O
recognition	O
by	O
IgGs	B-GP
from	O
anemic	O
and	O
non	O
-	O
anemic	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
with	O
acute	B-DS
malaria	I-DS

To	O
determine	O
whether	O
IgG	B-GP
antibodies	B-GP
recognizing	O
nRBC	O
antigens	O
are	O
increased	O
during	O
acute	O
P	B-DS
.	I-DS
vivax	I-DS
malaria	I-DS
,	O
median	O
levels	O
of	O
such	O
immunoglobulins	B-GP
were	O
assessed	O
by	O
ELISA	O
in	O
plasma	O
from	O
patients	O
with	O
patent	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
presenting	O
(	O
n	O
=	O
24	O
)	O
or	O
not	O
(	O
n	O
=	O
24	O
)	O
anemia	B-DS
,	O
as	O
well	O
as	O
in	O
plasma	O
from	O
healthy	O
individuals	O
never	O
exposed	O
to	O
malaria	B-DS
(	O
n	O
=	O
8	O
).	O

Anemic	O
patients	O
infected	O
with	O
P	B-OG
.	I-OG
vivax	I-OG
had	O
higher	O
levels	O
of	O
IgG	B-GP
against	O
erythrocyte	O
proteins	O
(	O
median	O
OD	O
:	O
0	O
.	O
49	O
;	O
IQR	O
[	O
0	O
.	O
41	O
–	O
0	O
.	O
65	O
])	O
than	O
the	O
infected	O
non	O
-	O
anemic	O
patients	O
(	O
median	O
OD	O
:	O
0	O
.	O
21	O
;	O
IQR	O
[	O
0	O
.	O
10	O
–	O
0	O
.	O
39	O
])	O
or	O
healthy	O
controls	O
(	O
median	O
OD	O
:	O
0	O
.	O
21	O
;	O
IQR	O
[	O
0	O
.	O
07	O
–	O
0	O
.	O
37	O
])	O
(	O
Kruskal	O
-	O
Wallis	O
followed	O
Dunn	O
’	O
s	O
post	O
hoc	O
test	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
(	O
Fig	O
.	O
1	O
).	O
Figure	O
1Levels	O
of	O
IgG	B-GP
against	O
protein	O
extracts	O
of	O
nRBCs	O
in	O
plasma	O
from	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
with	O
or	O
without	O
anemia	B-DS
.	O

IgG	B-GP
antibody	B-GP
responses	O
were	O
evaluated	O
by	O
ELISA	O
using	O
plasma	O
from	O
healthy	O
individuals	O
(	O
n	O
=	O
8	O
)	O
and	O
anemic	O
(	O
n	O
=	O
24	O
)	O
or	O
non	O
-	O
anemic	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
(	O
n	O
=	O
24	O
).	O

Results	O
are	O
shown	O
as	O
values	O
of	O
mean	O
optical	O
density	O
and	O
standard	O
error	O
of	O
the	O
mean	O
.	O

Differences	O
between	O
the	O
groups	O
were	O
determined	O
using	O
Kruskal	O
-	O
Wallis	O
test	O
followed	O
by	O
Dunn	O
post	O
hoc	O
test	O
(	O
p	O
value	O
<	O
0	O
.	O
0001	O
).	O

Comparative	O
analysis	O
of	O
the	O
immunoproteomes	O
obtained	O
with	O
serum	O
samples	O
of	O
the	O
three	O
experimental	O
groups	O
revealed	O
a	O
different	O
profile	O
of	O
antigenic	O
spots	O
.	O

Figure	O
2	O
shows	O
a	O
representative	O
nRBC	O
2D	O
-	O
SDS	O
-	O
PAGE	O
map	O
.	O

Sera	O
from	O
the	O
infected	O
groups	O
recognized	O
a	O
greater	O
number	O
of	O
spots	O
than	O
the	O
sera	O
from	O
the	O
healthy	O
control	O
group	O
(	O
Fig	O
.	O
3	O
).	O

Some	O
of	O
the	O
spots	O
recognized	O
exclusively	O
by	O
the	O
serum	O
antibodies	B-GP
of	O
patients	O
with	O
vivax	B-DS
malaria	I-DS
corresponded	O
to	O
cytoplasmic	O
proteins	O
bound	O
to	O
the	O
cell	O
membrane	O
such	O
as	O
ankyrin	B-GP
,	O
dematin	B-GP
7	I-GP
,	O
and	O
band	B-GP
4	I-GP
.	I-GP
2	I-GP
(	O
Fig	O
.	O
3	O
,	O
Supplementary	O
Tables	O
1	O
and	O
2	O
).	O

Several	O
spots	O
corresponded	O
to	O
membrane	B-GP
-	I-GP
cytoskeleton	I-GP
associated	I-GP
proteins	I-GP
,	O
spectrins	B-GP
and	O
actin	B-GP
.	O

Spots	O
corresponding	O
to	O
the	O
integral	B-GP
membrane	I-GP
protein	I-GP
band	B-GP
3	I-GP
were	O
also	O
identified	O
(	O
Fig	O
.	O
3	O
,	O
Supplementary	O
Tables	O
1	O
and	O
2	O
).	O

We	O
also	O
detected	O
other	O
proteins	O
that	O
were	O
recognized	O
by	O
antibodies	B-GP
from	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
,	O
but	O
which	O
were	O
not	O
confirmed	O
by	O
peptide	O
sequencing	O
:	O
EV15	B-GP
-	I-GP
like	I-GP
protein	I-GP
,	O
kynurenine	B-GP
-	I-GP
oxoglutarate	I-GP
transaminase	I-GP
,	O
long	B-GP
chain	I-GP
fatty	I-GP
acid	I-GP
transport	I-GP
protein	I-GP
6	I-GP
,	O
FAM45A	B-GP
protein	O
,	O
FAM180A	B-GP
,	O
and	O
TMLHE	B-GP
(	O
Fig	O
.	O
3	O
,	O
Supplementary	O
Table	O
1	O
).	O

Spots	O
recognized	O
exclusively	O
by	O
sera	O
from	O
anemic	O
malaria	B-DS
patients	O
included	O
band	B-GP
3	I-GP
,	O
spectrin	B-GP
(	O
both	O
alpha	O
and	O
beta	O
chains	O
),	O
cytoplasmic	B-GP
actin	I-GP
1	I-GP
,	O
protein	B-GP
4	I-GP
.	I-GP
1	I-GP
,	O
protein	B-GP
band	I-GP
4	I-GP
.	I-GP
2	I-GP
,	O
ankyrin	B-GP
1	I-GP
,	O
and	O
dematin	B-GP
(	O
Fig	O
.	O
3	O
,	O
Supplementary	O
Table	O
1	O
).	O
Figure	O
2Representative	O
2D	O
-	O
SDS	O
-	O
PAGE	O
map	O
of	O
RBC	O
protein	O
spots	O
identified	O
by	O
mass	O
spectrometry	O
.	O

100	O
µg	O
of	O
nRBCs	O
protein	O
extract	O
were	O
focused	O
on	O
pH	O
4	O
–	O
7	O
IPG	O
strips	O
(	O
7	O
cm	O
)	O
and	O
then	O
separated	O
by	O
SDS	O
-	O
PAGE	O
12	O
%.	O

Gel	O
was	O
stained	O
with	O
colloidal	O
Coomassie	O
Blue	O
G	O
-	O
250	O
.	O

The	O
molecular	O
masses	O
(	O
kDa	O
)	O
of	O
the	O
protein	O
standards	O
are	O
indicated	O
on	O
the	O
left	O
.	O

All	O
the	O
protein	O
spots	O
that	O
matched	O
to	O
their	O
corresponding	O
spot	O
in	O
the	O
western	O
blotting	O
were	O
excised	O
from	O
the	O
gel	O
and	O
processed	O
for	O
MALDI	O
-	O
ToF	O
/	O
ToF	O
mass	O
spectrometry	O
analysis	O
.	O

These	O
protein	O
spots	O
are	O
listed	O
in	O
the	O
Supplementary	O
Tables	O
1	O
and	O
2	O
.	O
Figure	O
3Comparative	O
analysis	O
of	O
the	O
IgG	B-GP
repertoire	O
against	O
nRBC	O
proteins	O
among	O
subjects	O
with	O
distinct	O
vivax	B-DS
malaria	I-DS
clinical	O
features	O
.	O

The	O
proteins	O
resolved	O
by	O
2D	O
-	O
SDS	O
-	O
PAGE	O
were	O
blotted	O
onto	O
PVDF	O
membranes	O
and	O
probed	O
with	O
different	O
plasma	O
pools	O
:	O
(	O
A	O
)	O
healthy	O
,	O
(	O
B	O
)	O
patients	O
with	O
vivax	B-DS
malaria	I-DS
and	O
no	O
anemia	B-DS
or	O
(	O
C	O
)	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
with	O
anemia	B-DS
.	O

Bound	O
antibodies	B-GP
were	O
detected	O
with	O
HRP	B-GP
conjugated	O
anti	O
-	O
human	B-OG
IgG	B-GP
(	O
1	O
:	O
6000	O
)	O
using	O
an	O
ECL	O
chemiluminescence	O
-	O
based	O
kit	O
.	O

Images	O
were	O
analysed	O
using	O
ImageMaster	O
2D	O
Platinum	O
software	O
(	O
GE	O
).	O

A	O
representative	O
image	O
of	O
three	O
independent	O
experiments	O
is	O
shown	O
.	O

Western	O
blots	O
were	O
cropped	O
for	O
easier	O
visualization	O
;	O
uncropped	O
images	O
are	O
available	O
in	O
the	O
supplemental	O
material	O
.	O

All	O
the	O
protein	O
spots	O
detected	O
in	O
the	O
Western	O
blotting	O
that	O
matched	O
to	O
their	O
corresponding	O
spot	O
in	O
2D	O
-	O
SDS	O
-	O
PAGE	O
gel	O
were	O
processed	O
for	O
MALDI	O
-	O
ToF	O
/	O
ToF	O
mass	O
spectrometry	O
analysis	O
and	O
are	O
listed	O
in	O
the	O
supplementary	O
Tables	O
1	O
and	O
2	O
.	O

Anti	O
-	O
band	B-GP
3	I-GP
and	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
correlate	O
with	O
anemia	B-DS
in	O
patients	O
with	O
vivax	B-DS
malaria	I-DS

Since	O
band	B-GP
3	I-GP
and	O
spectrin	B-GP
proteins	O
are	O
involved	O
in	O
RBC	O
clearance	O
,	O
we	O
selected	O
them	O
to	O
validate	O
the	O
findings	O
of	O
the	O
immunoproteomic	O
approach	O
.	O

To	O
detect	O
anti	O
-	O
band	B-GP
3	I-GP
and	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
in	O
plasma	O
from	O
patients	O
with	O
patent	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
,	O
we	O
used	O
ELISA	O
.	O

IgG	B-GP
levels	O
were	O
expressed	O
as	O
reactivity	O
index	O
,	O
which	O
was	O
obtained	O
by	O
dividing	O
the	O
mean	O
OD	O
value	O
of	O
each	O
test	O
sample	O
by	O
the	O
cut	O
-	O
off	O
value	O
(	O
threshold	O
of	O
positivity	O
).	O

The	O
cut	O
off	O
value	O
was	O
calculated	O
as	O
the	O
mean	O
OD	O
plus	O
two	O
standard	O
deviations	O
of	O
eight	O
healthy	O
blood	O
donors	O
never	O
exposed	O
to	O
malaria	B-DS
as	O
it	O
will	O
be	O
described	O
in	O
section	O
4	O
.	O
8	O
.	O

We	O
observed	O
that	O
anemic	O
patients	O
had	O
significantly	O
higher	O
levels	O
of	O
anti	O
-	O
band	B-GP
3	I-GP
antibodies	B-GP
(	O
median	O
:	O
1	O
.	O
69	O
;	O
ITR	O
:	O
[	O
0	O
.	O
97	O
–	O
3	O
.	O
12	O
])	O
in	O
comparison	O
to	O
the	O
non	O
-	O
anemic	O
ones	O
(	O
median	O
:	O
0	O
.	O
39	O
;	O
ITR	O
:	O
[	O
0	O
.	O
21	O
–	O
0	O
.	O
69	O
])	O
(	O
Mann	O
-	O
Whitney	O
U	O
test	O
p	O
<	O
0	O
.	O
0001	O
,	O
Fig	O
.	O
4A	O
).	O

A	O
similar	O
result	O
was	O
also	O
observed	O
for	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
(	O
median	O
of	O
0	O
.	O
85	O
,	O
ITR	O
[	O
0	O
.	O
68	O
–	O
1	O
.	O
38	O
]	O
for	O
anemic	O
versus	O
median	O
of	O
0	O
.	O
59	O
,	O
ITR	O
[	O
0	O
.	O
46	O
–	O
0	O
.	O
78	O
]	O
for	O
the	O
non	O
-	O
anemic	O
;	O
Mann	O
-	O
Whitney	O
U	O
test	O
p	O
=	O
0	O
.	O
0043	O
).	O
Figure	O
4Anti	O
-	O
band	B-GP
3	I-GP
and	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
correlate	O
with	O
anemia	B-DS
in	O
patients	O
with	O
acute	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
.	O

Levels	O
of	O
anti	O
-	O
band	B-GP
3	I-GP
and	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
were	O
detected	O
by	O
ELISA	O
in	O
plasma	O
samples	O
from	O
patients	O
with	O
patent	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
presenting	O
or	O
not	O
presenting	O
anemia	B-DS
.	O

Antibody	B-GP
levels	O
were	O
expressed	O
as	O
reactivity	O
index	O
(	O
RI	O
),	O
which	O
was	O
calculated	O
as	O
the	O
ratio	O
between	O
the	O
mean	O
OD	O
generated	O
by	O
each	O
test	O
sample	O
and	O
the	O
mean	O
OD	O
plus	O
two	O
standard	O
deviations	O
of	O
samples	O
from	O
eight	O
healthy	O
blood	O
donors	O
never	O
exposed	O
to	O
malaria	B-DS
.	O

RIs	O
equal	O
or	O
greater	O
than	O
1	O
.	O
0	O
were	O
scored	O
as	O
positive	O
(	O
A	O
)	O
Anti	O
-	O
band	B-GP
3	I-GP
and	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
levels	O
were	O
compared	O
between	O
anemic	O
(	O
n	O
=	O
24	O
)	O
and	O
non	O
-	O
anemic	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
(	O
n	O
=	O
24	O
)	O
using	O
Mann	O
-	O
Whitney	O
test	O
.	O

Scatter	O
plots	O
show	O
the	O
means	O
and	O
standard	O
deviations	O
.	O

The	O
dotted	O
lines	O
on	O
each	O
graph	O
represent	O
the	O
threshold	O
above	O
which	O
samples	O
were	O
considered	O
as	O
positive	O
.	O

(	O
B	O
)	O
Heat	O
map	O
of	O
IgG	B-GP
antibody	B-GP
profile	O
against	O
band	B-GP
3	I-GP
and	O
spectrin	B-GP
in	O
plasma	O
from	O
anemic	O
and	O
non	O
-	O
anemic	O
patients	O
with	O
vivax	B-DS
malaria	I-DS
.	O

Grey	O
colour	O
indicates	O
that	O
antibody	B-GP
levels	O
are	O
at	O
least	O
greater	O
than	O
the	O
mean	O
plus	O
two	O
standard	O
deviations	O
of	O
the	O
healthy	O
controls	O
whereas	O
white	O
colour	O
denotes	O
the	O
opposite	O
result	O
.	O

Associations	O
between	O
hemoglobin	B-GP
levels	O
and	O
anti	O
-	O
band	B-GP
3	I-GP
or	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
(	O
C	O
and	O
D	O
,	O
respectively	O
)	O
were	O
analysed	O
by	O
Spearman	O
correlation	O
.	O

To	O
further	O
understand	O
each	O
patient	O
´	O
s	O
individual	O
immunoreactivity	O
profile	O
against	O
these	O
two	O
erythrocytic	O
antigens	O
,	O
a	O
heatmap	O
was	O
used	O
(	O
Fig	O
.	O
4B	O
).	O

We	O
observed	O
that	O
the	O
spectra	O
of	O
antibody	B-GP
responses	O
varied	O
markedly	O
among	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
either	O
presenting	O
or	O
not	O
presenting	O
anemia	B-DS
.	O

For	O
evaluating	O
whether	O
there	O
is	O
a	O
direct	O
correlation	O
between	O
hemoglobin	B-GP
levels	O
and	O
anti	O
-	O
RBC	O
antibodies	B-GP
,	O
the	O
levels	O
of	O
hemoglobin	B-GP
were	O
correlated	O
with	O
the	O
levels	O
of	O
anti	O
-	O
band	B-GP
3	I-GP
or	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
(	O
Fig	O
.	O
4C	O
,	O
D	O
,	O
respectively	O
).	O

The	O
data	O
clearly	O
show	O
that	O
the	O
levels	O
of	O
hemoglobin	B-GP
decreases	O
with	O
the	O
increase	O
in	O
the	O
level	O
of	O
anti	O
-	O
band	B-GP
3	I-GP
(	O
Spearman	O
correlation	O
:	O
r	O
=	O
−	O
0	O
.	O
7224	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

A	O
similar	O
association	O
was	O
also	O
found	O
to	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
(	O
Spearman	O
correlation	O
:	O
r	O
=	O
−	O
0	O
.	O
3321	O
;	O
p	O
=	O
0	O
.	O
0211	O
).	O

In	O
silico	O
identification	O
of	O
cross	O
-	O
reactive	O
proteins	O
between	O
host	O
RBCs	O
and	O
P	B-OG
.	I-OG
vivax	I-OG

We	O
hypothesized	O
that	O
the	O
observed	O
autoimmune	O
response	O
could	O
be	O
due	O
to	O
molecular	O
mimicry	O
.	O

Therefore	O
,	O
we	O
performed	O
an	O
in	O
silico	O
analysis	O
comparing	O
P	B-OG
.	I-OG
vivax	I-OG
entire	O
proteome	O
and	O
human	B-OG
RBC	O
proteome	O
to	O
identify	O
putative	O
molecular	O
mimicry	O
candidate	O
proteins	O
.	O

The	O
final	O
BLAST	O
results	O
indicated	O
that	O
23	O
P	B-OG
.	I-OG
vivax	I-OG
proteins	O
were	O
mimetic	O
to	O
human	B-OG
RBC	O
proteins	O
(	O
Table	O
1	O
).	O

Nineteen	O
of	O
them	O
were	O
hypothetical	O
proteins	O
of	O
the	O
parasite	O
and	O
their	O
mimetic	O
human	B-OG
RBC	O
proteins	O
were	O
associated	O
with	O
plasma	O
membranes	O
:	O
ankyrin	B-GP
,	O
actin	B-GP
,	O
and	O
spectrin	B-GP
(	O
Table	O
1	O
).	O

The	O
other	O
four	O
parasite	O
proteins	O
found	O
to	O
be	O
mimetic	O
to	O
human	B-OG
RBC	O
proteins	O
(	O
PVX_123515	B-GP
,	O
PVX_099980	B-GP
,	O
PVX_101610	B-GP
and	O
PVX_099980	B-GP
)	O
were	O
membrane	O
surface	O
-	O
related	O
proteins	O
.	O

Interestingly	O
,	O
most	O
of	O
the	O
candidates	O
were	O
also	O
membrane	O
-	O
associated	O
RBC	O
proteins	O
such	O
as	O
the	O
ones	O
found	O
in	O
the	O
immunoproteomic	O
approach	O
(	O
Fig	O
.	O
3	O
,	O
Supplementary	O
Tables	O
1	O
and	O
2	O
).	O
Table	O
1P	O
.	O
vivax	B-OG
proteins	O
mimetic	O
to	O
human	B-OG
proteins	O
.	O
Subject	O
Human	B-OG
ID	O
P	B-OG
.	I-OG
vivax	I-OG
query	O
ID	O
Protein	O
description	O
(	O
P	B-OG
.	I-OG
vivax	I-OG
)	O
Human	B-OG
protein	O
sp	O
|	O
O60641	O
|	O
AP180_HUMANPVX_092010	B-GP
-	O
AA	O
:	O
777hypothetical	O
protein	O
,	O
conservedClathrin	B-GP
coat	I-GP
assembly	I-GP
protein	I-GP
AP180sp	I-GP
|	O
O94856	O
|	O
NFASC_HUMANPVX_095335	B-GP
-	O
AA	O
:	O
266hypothetical	O
protein	O
,	O
conservedNeurofascinsp	B-GP
|	O
O94988	O
|	O
FA13A_HUMANPVX_123250	B-GP
-	O
AA	O
:	O
290hypothetical	O
protein	O
,	O
conservedProtein	B-GP
FAM13Asp	I-GP
|	O
P07205	O
|	O
PGK2_HUMANPVX_123515	B-GP
-	O
AA	O
:	O
1081MAC	B-GP
/	I-GP
Perforin	I-GP
domain	I-GP
containing	I-GP
proteinPhosphoglycerate	I-GP
kinase	I-GP
2sp	I-GP
|	O
P35611	O
|	O
ADDA_HUMANPVX_099980	B-GP
-	O
AA	O
:	O
800major	O
blood	O
-	O
stage	O
surface	O
antigen	O
Pv200Alpha	B-GP
-	I-GP
adducinsp	I-GP
|	O
P55209	O
|	O
NP1L1_HUMANPVX_091530	B-GP
-	O
AA	O
:	O
524hypothetical	O
protein	O
,	O
conservedNucleosome	B-GP
assembly	I-GP
protein	I-GP
1	I-GP
-	I-GP
like	I-GP
1sp	I-GP
|	O
P78356	O
|	O
PI42B_HUMANPVX_099150	B-GP
-	O
AA	O
:	O
363hypothetical	O
protein	O
,	O
conservedPhosphatidylinositol	B-GP
5	I-GP
-	I-GP
phosphate	I-GP
4	I-GP
-	I-GP
kinase	I-GP
type	I-GP
-	I-GP
2	I-GP
betasp	I-GP
|	O
Q12873	O
|	O
CHD3_HUMANPVX_093655	B-GP
-	O
AA	O
:	O
1234hypothetical	O
protein	O
,	O
conservedChromodomain	B-GP
-	I-GP
helicase	I-GP
-	I-GP
DNA	I-GP
-	I-GP
binding	I-GP
protein	I-GP
3sp	I-GP
|	O
Q13151	O
|	O
ROA0_HUMANPVX_092895	B-GP
-	O
AA	O
:	O
619hypothetical	O
protein	O
,	O
conservedHeterogeneous	B-GP
nuclear	I-GP
ribonucleoprotein	I-GP
A0sp	I-GP
|	O
Q13637	O
|	O
RAB32_HUMANPVX_123100	B-GP
-	O
AA	O
:	O
280hypothetical	O
protein	O
,	O
conservedRas	B-GP
-	I-GP
related	I-GP
protein	I-GP
Rab	I-GP
-	I-GP
32sp	I-GP
|	O
Q5S007	O
|	O
LRRK2_HUMANPVX_000660	B-GP
-	O
AA	O
:	O
258hypothetical	O
proteinLeucine	B-GP
-	I-GP
rich	I-GP
repeat	I-GP
serine	I-GP
/	I-GP
threonine	I-GP
-	I-GP
protein	I-GP
kinase	I-GP
2sp	I-GP
|	O
Q6PL18	O
|	O
ATAD2_HUMANPVX_101610	B-GP
-	O
AA	O
:	O
137RAD	B-GP
protein	I-GP
(	I-GP
Pv	I-GP
-	I-GP
fam	I-GP
-	I-GP
e	I-GP
)	I-GP
ATPase	B-GP
family	I-GP
AAA	I-GP
domain	I-GP
-	I-GP
containing	I-GP
protein	I-GP
2sp	I-GP
|	O
Q6WRI0	O
|	O
IGS10_HUMANPVX_085900	B-GP
-	O
AA	O
:	O
1308hypothetical	O
protein	O
,	O
conservedImmunoglobulin	B-GP
superfamily	I-GP
member	I-GP
10sp	I-GP
|	O
Q6ZRI8	O
|	O
RHG36_HUMANPVX_114675	B-GP
-	O
AA	O
:	O
140hypothetical	O
protein	O
,	O
conservedRho	B-GP
GTPase	I-GP
-	I-GP
activating	I-GP
protein	I-GP
36sp	I-GP
|	O
Q9BQ39	O
|	O
DDX50_HUMANPVX_117850	B-GP
-	O
AA	O
:	O
2285hypothetical	O
protein	O
,	O
conservedATP	B-GP
-	I-GP
dependent	I-GP
RNA	I-GP
helicase	I-GP
DDX50sp	I-GP
|	O
Q9BYB0	O
|	O
SHAN3_HUMANPVX_122920	B-GP
-	O
AA	O
:	O
552hypothetical	O
protein	O
,	O
conservedSH3	B-GP
and	I-GP
multiple	I-GP
ankyrin	I-GP
repeat	I-GP
domains	I-GP
protein	I-GP
3sp	I-GP
|	O
Q9BZF9	O
|	O
UACA_HUMANPVX_099150	B-GP
-	O
AA	O
:	O
822hypothetical	O
protein	O
,	O
conservedUveal	B-GP
autoantigen	I-GP
with	I-GP
coiled	I-GP
-	I-GP
coil	I-GP
domains	I-GP
and	I-GP
ankyrin	I-GP
repeatssp	I-GP
|	O
Q9H254	O
|	O
SPTN4_HUMANPVX_003755	B-GP
-	O
AA	O
:	O
415hypothetical	O
protein	O
,	O
conservedSpectrin	B-GP
beta	I-GP
chain	I-GP
,	I-GP
brain	I-GP
3sp	I-GP
|	O
Q9H4A3	O
|	O
WNK1_HUMANPVX_118355	B-GP
-	O
AA	O
:	O
350hypothetical	O
proteinSerine	B-GP
/	I-GP
threonine	I-GP
-	I-GP
protein	I-GP
kinase	I-GP
WNK1sp	I-GP
|	O
Q9NQC3	O
|	O
RTN4_HUMANPVX_099980	B-GP
-	O
AA	O
:	O
809major	O
blood	O
-	O
stage	O
surface	O
antigen	O
Pv200Reticulon	B-GP
-	I-GP
4sp	I-GP
|	O
Q9P0M6	O
|	O
H2AW_HUMANPVX_083455	B-GP
-	O
AA	O
:	O
988hypothetical	O
protein	O
,	O
conservedCore	B-GP
histone	I-GP
macro	I-GP
-	I-GP
H2A	I-GP
.	I-GP
2sp	I-GP
|	O
Q9UPE1	O
|	O
SRPK3_HUMANPVX_123910	B-GP
-	O
AA	O
:	O
330hypothetical	O
protein	O
,	O
conservedSRSF	B-GP
protein	I-GP
kinase	I-GP
3sp	I-GP
|	O
Q9UPN3	O
|	O
MACF1_HUMANPVX_099150	B-GP
-	O
AA	O
:	O
569hypothetical	O
protein	O
,	O
conservedMicrotubule	B-GP
-	I-GP
actin	I-GP
cross	I-GP
-	I-GP
linking	I-GP
factor	I-GP
1	I-GP
,	I-GP
isoforms	I-GP
1	I-GP
/	O
2	O
/	O
3	O
/	O
5	O

Comparison	O
between	O
the	O
spectrin	B-GP
sequence	O
of	O
P	B-OG
.	I-OG
vivax	I-OG
and	O
other	O
Plasmodium	B-OG
species	O

Since	O
autoantibodies	B-GP
from	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
recognized	O
spectrin	B-GP
and	O
this	O
protein	O
was	O
identified	O
in	O
our	O
mimicry	O
in	O
silico	O
approach	O
,	O
we	O
also	O
verified	O
if	O
spectrin	B-GP
was	O
conserved	O
in	O
other	O
Plasmodium	B-OG
species	O
.	O

The	O
sequence	O
that	O
seemed	O
the	O
most	O
ideal	O
for	O
comparative	O
analysis	O
was	O
the	O
hypothetical	O
P	B-OG
.	I-OG
vivax	I-OG
protein	O
(	O
PVX_003755	B-GP
),	O
which	O
was	O
mimetic	O
to	O
the	O
human	B-OG
spectrin	B-GP
β	I-GP
-	I-GP
chain	I-GP
.	O

We	O
aligned	O
this	O
P	B-OG
.	I-OG
vivax	I-OG
spectrin	B-GP
-	O
like	O
sequence	O
with	O
other	O
Plasmodium	B-OG
species	O
using	O
blastp	O
and	O
verified	O
that	O
all	O
local	O
alignments	O
corresponded	O
to	O
hypothetical	O
proteins	O
(	O
Table	O
2	O
).	O

Our	O
orthology	O
analysis	O
revealed	O
no	O
paralog	O
sequences	O
in	O
the	O
ortholog	O
clusters	O
.	O

The	O
phylogenetic	O
analysis	O
identified	O
at	O
least	O
two	O
evolutionary	O
groups	O
(	O
P1	O
and	O
P2	O
)	O
for	O
this	O
protein	O
and	O
showed	O
that	O
P	B-OG
.	I-OG
falciparum	I-OG
was	O
the	O
species	O
whose	O
spectrin	B-GP
sequence	O
appeared	O
to	O
be	O
the	O
most	O
divergent	O
in	O
comparison	O
with	O
the	O
sequences	O
from	O
other	O
Plasmodium	B-OG
species	O
(	O
Fig	O
.	O
5A	O
).	O
Table	O
2Plasmodium	B-OG
spectrin	B-GP
-	O
like	O
ortholog	O
sequences	O
.	O
GeneOrganismProductLengthPBANKA_0304100Plasmodium	B-OG
berghei	I-OG
ANKAhypothetical	I-OG
protein	O
,	O
conserved1030PCHAS_0306300	O
Plasmodium	B-OG
chabaudi	O
chabaudi	O
hypothetical	O
protein	O
,	O
conserved1027PCYB_042380Plasmodium	B-OG
cynomolgi	I-OG
strain	I-OG
Bhypothetical	I-OG
protein	O
,	O
conserved840PF3D7_0206500Plasmodium	B-OG
falciparum	I-OG
3D7hypothetical	I-OG
protein	O
,	O
conserved1436PKNH_0414500Plasmodium	B-OG
knowlesi	I-OG
strain	I-OG
Hhypothetical	I-OG
protein	O
,	O
conserved1101PY17X_0304700Plasmodium	B-OG
yoelii	I-OG
yoelii	I-OG
17Xhypothetical	I-OG
protein	O
,	O
conserved983PY00070Plasmodium	B-OG
yoelii	I-OG
yoelii	I-OG
17XNLhypothetical	I-OG
protein958PYYM_0305000Plasmodium	B-OG
yoelii	I-OG
yoelii	I-OG
YMhypothetical	I-OG
protein	O
,	O
conserved983PVX_003755Plasmodium	B-OG
vivax	I-OG
SaI	I-OG
-	I-OG
1hypothetical	I-OG
protein	O
,	O
conserved1085Figure	O
5Comparison	O
of	O
the	O
divergence	O
of	O
spectrin	B-GP
-	I-GP
like	I-GP
proteins	I-GP
between	O
different	O
Plasmodium	B-OG
species	O
.	O

(	O
A	O
)	O
Plasmodium	B-OG
“	O
spectrin	B-GP
-	O
like	O
”	O
maximum	O
likelihood	O
phylogenetic	O
tree	O
.	O

Two	O
groups	O
are	O
detected	O
:	O
one	O
group	O
containing	O
the	O
Plasmodium	B-OG
falciparum	I-OG
protein	O
(	O
P1	O
)	O
and	O
the	O
other	O
with	O
the	O
P	B-OG
.	I-OG
vivax	I-OG
protein	O
(	O
P2	O
);	O
P1	O
and	O
P2	O
represents	O
the	O
two	O
putative	O
phylogenetic	O
groups	O
of	O
spectrin	B-GP
-	O
like	O
sequences	O
between	O
the	O
analyzed	O
Plasmodium	B-OG
species	O
.	O

(	O
B	O
)	O
P	B-OG
.	I-OG
falciparum	I-OG
protein	O
Pf3D7_0206500	B-GP
synteny	O
alignment	O
against	O
all	O
other	O
Plasmodium	B-OG
species	O
spectrin	B-GP
-	I-GP
like	I-GP
proteins	I-GP
.	O

The	O
figure	O
shows	O
that	O
the	O
C	O
-	O
terminus	O
(	O
red	O
end	O
)	O
is	O
highly	O
conserved	O
in	O
all	O
proteins	O
and	O
the	O
N	O
-	O
terminus	O
(	O
green	O
end	O
)	O
is	O
only	O
conserved	O
in	O
the	O
group	O
B	O
sequences	O
.	O

Only	O
alignments	O
with	O
more	O
than	O
75	O
%	O
identity	O
were	O
represented	O
in	O
this	O
figure	O
.	O

The	O
conserved	O
C	O
-	O
terminus	O
region	O
among	O
all	O
species	O
is	O
mimetic	O
to	O
the	O
human	B-OG
pleckstrin	B-GP
-	O
like	O
homology	O
domain	O
(	O
PH	O
domain	O
).	O

We	O
performed	O
a	O
sequence	O
identity	O
comparison	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
Pf3D7_0206500	B-GP
against	O
all	O
other	O
Plasmodium	B-OG
species	O
spectrin	B-GP
-	I-GP
like	I-GP
proteins	I-GP
.	O

One	O
may	O
observe	O
two	O
different	O
patterns	O
in	O
our	O
dataset	O
:	O
the	O
C	O
-	O
terminus	O
of	O
all	O
the	O
proteins	O
was	O
highly	O
conserved	O
while	O
the	O
N	O
-	O
terminus	O
region	O
showed	O
identity	O
to	O
P	B-OG
.	I-OG
falciparum	I-OG
only	O
for	O
proteins	O
from	O
the	O
group	O
P2	O
(	O
Fig	O
.	O
5B	O
).	O

When	O
using	O
all	O
other	O
Plasmodium	B-OG
sequences	O
as	O
queries	O
we	O
saw	O
that	O
they	O
maintained	O
the	O
same	O
identity	O
pattern	O
in	O
the	O
N	O
-	O
terminus	O
except	O
for	O
P	B-OG
.	I-OG
cynomolgi	I-OG
,	O
which	O
seems	O
to	O
have	O
a	O
smaller	O
size	O
gene	O
,	O
caused	O
by	O
a	O
mutation	O
or	O
by	O
an	O
annotation	O
error	O
.	O

Discussion	O

Our	O
data	O
provide	O
information	O
about	O
autoantibody	B-GP
responses	O
to	O
non	O
-	O
infected	O
RBCs	O
as	O
well	O
as	O
its	O
association	O
with	O
anemia	B-DS
during	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
.	O

Using	O
different	O
approaches	O
,	O
we	O
found	O
that	O
:	O
(	O
1	O
)	O
anemic	O
patients	O
infected	O
with	O
P	B-OG
.	I-OG
vivax	I-OG
have	O
higher	O
levels	O
of	O
IgG	B-GP
against	O
erythrocyte	O
proteins	O
;	O
(	O
2	O
)	O
band	B-GP
3	I-GP
and	O
spectrin	B-GP
proteins	O
are	O
the	O
main	O
molecular	O
targets	O
in	O
nRBCs	O
differentially	O
recognized	O
by	O
IgGs	B-GP
from	O
anemic	O
patients	O
with	O
patent	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
;	O
and	O
(	O
3	O
)	O
a	O
P	B-OG
.	I-OG
vivax	I-OG
protein	O
of	O
unknown	O
function	O
is	O
mimetic	O
to	O
human	B-OG
spectrin	B-GP
suggesting	O
that	O
molecular	O
mimicry	O
may	O
contribute	O
to	O
autoantibody	B-GP
immune	O
responses	O
to	O
nRBCs	O
.	O

Many	O
RBC	O
protein	O
spots	O
were	O
recognized	O
by	O
autoantibodies	B-GP
of	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
rather	O
than	O
by	O
autoantibodies	B-GP
from	O
healthy	O
sera	O
.	O

Previous	O
results	O
of	O
our	O
group	O
revealed	O
that	O
non	O
-	O
infected	O
RBC	O
have	O
reductions	O
in	O
their	O
dynamic	O
membrane	O
fluctuations	O
when	O
incubated	O
with	O
autoantibodies	B-GP
from	O
patients	O
with	O
P	B-DS
.	I-DS
vivax	I-DS
malaria19	I-DS
.	O

The	O
immunoproteomic	O
data	O
presented	O
here	O
show	O
that	O
antibodies	B-GP
from	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
subjects	O
recognize	O
proteins	O
such	O
as	O
band	B-GP
3	I-GP
,	O
spectrin	B-GP
and	O
actin	B-GP
.	O

Since	O
the	O
transmembrane	O
band	B-GP
3	I-GP
exposes	O
new	O
antigens	O
during	O
Plasmodium	B-DS
infection20	I-DS
,	O
21	O
,	O
it	O
is	O
a	O
more	O
probable	O
target	O
of	O
autoantibodies	B-GP
than	O
the	O
cytoskeletal	B-GP
proteins	I-GP
.	O

Shibuya	O
et	O
al	O
.	O
(	O
2018	O
)	O
proposed	O
a	O
model	O
for	O
antibody	B-GP
assess	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
band	B-GP
3	I-GP
in	O
hereditary	B-DS
spherocytosis	I-DS
,	O
which	O
was	O
attributed	O
to	O
the	O
hydrolysis	O
of	O
spectrin	B-GP
and	O
ankyrin	B-GP
.	O

Their	O
proposal	O
is	O
that	O
conformational	O
changes	O
in	O
the	O
extracellular	O
portion	O
of	O
band	B-GP
3	I-GP
protein	O
observed	O
in	O
patients	O
with	O
hereditary	B-DS
spherocytosis	I-DS
would	O
lead	O
to	O
the	O
hydrolysis	O
of	O
spectrin	B-GP
and	O
ankyrin	B-GP
in	O
the	O
intracellular	O
milieu	O
,	O
which	O
directly	O
affects	O
cytoskeleton	O
dynamics	O
,	O
leading	O
to	O
RBC	O
clearance	O
.	O

In	O
this	O
scenario	O
,	O
the	O
binding	O
of	O
anti	O
-	O
band	B-GP
3	I-GP
autoantibodies	B-GP
to	O
band	B-GP
3	I-GP
protein	O
on	O
the	O
surface	O
of	O
RBC	O
during	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
could	O
induce	O
similar	O
intracellular	O
changes	O
,	O
affecting	O
cytoskeleton	O
and	O
leading	O
to	O
a	O
higher	O
clearance	O
of	O
erythrocytes	O
.	O

Although	O
the	O
presence	O
of	O
autoantibodies	B-GP
against	O
RBCs	O
has	O
been	O
previously	O
reported	O
in	O
vivax	B-DS
infection16	I-DS
,	O
only	O
recently	O
we	O
demonstrated	O
that	O
autoantibodies	B-GP
mediate	O
erythrophagocytosis	O
of	O
nRBCs	O
possibly	O
through	O
a	O
decrease	O
in	O
cell	O
deformability19	O
.	O

IgG	B-GP
autoantibodies	B-GP
of	O
anemic	O
patients	O
infected	O
by	O
P	B-OG
.	I-OG
vivax	I-OG
recognized	O
a	O
larger	O
number	O
of	O
erythrocytic	O
antigens	O
when	O
compared	O
to	O
non	O
-	O
anemic	O
individuals	O
.	O

Some	O
spots	O
exclusively	O
recognized	O
by	O
autoantibodies	B-GP
from	O
anemic	O
vivax	B-OG
patients	O
were	O
identified	O
as	O
band	B-GP
3	I-GP
protein	O
,	O
an	O
anion	B-GP
transporter	I-GP
that	O
mediates	O
cell	O
flexibility	O
and	O
shape	O
maintenance22	O
.	O

In	O
Plasmodium	B-DS
infections	I-DS
,	O
band	B-GP
3	I-GP
acts	O
as	O
a	O
host	O
receptor	O
for	O
interaction	O
with	O
different	O
merozoite	B-GP
proteins	I-GP
such	O
as	O
MSP	B-GP
-	I-GP
123	I-GP
,	O
MSP	B-GP
-	I-GP
924	I-GP
,	O
and	O
tryptophan	O
-	O
rich	O
antigens25	O
,	O
26	O
.	O

In	O
endemic	O
areas	O
where	O
P	B-OG
.	I-OG
falciparum	I-OG
is	O
the	O
prevalent	O
species	O
,	O
band	B-GP
3	I-GP
antibodies	B-GP
seem	O
to	O
be	O
protective	O
because	O
children	O
with	O
higher	O
levels	O
of	O
these	O
antibodies	B-GP
had	O
lower	O
parasitemia	B-DS
than	O
nonimmune	O
ones27	O
,	O
28	O
.	O

However	O
,	O
the	O
role	O
of	O
autoantibodies	B-GP
against	O
band	B-GP
3	I-GP
remains	O
controversial	O
and	O
has	O
never	O
been	O
studied	O
in	O
P	B-DS
.	I-DS
vivax	I-DS
infections	I-DS
.	O

We	O
speculate	O
that	O
such	O
autoantibodies	B-GP
may	O
contribute	O
to	O
anemia	B-DS
by	O
interacting	O
with	O
new	O
exposed	O
epitopes	O
followed	O
by	O
C3b	O
deposition	O
on	O
nRBCs21	O
,	O
by	O
promoting	O
erythrocyte	O
clearance29	O
and	O
by	O
changing	O
cell	O
membrane	O
deformability19	O
.	O

Band	B-GP
3	I-GP
has	O
a	O
cytoplasmic	O
domain	O
,	O
which	O
binds	O
to	O
different	O
proteins	O
involved	O
in	O
RBC	O
structure	O
and	O
function	O
,	O
and	O
a	O
transmembrane	O
domain	O
,	O
which	O
catalyses	O
the	O
chloride	B-GP
and	I-GP
bicarbonate	I-GP
antiporter	I-GP
transport22	O
,	O
30	O
.	O

Also	O
,	O
while	O
one	O
-	O
third	O
of	O
band	B-GP
3	I-GP
molecules	O
binds	O
to	O
spectrin	B-GP
and	O
becomes	O
immobile	O
,	O
the	O
other	O
two	O
-	O
thirds	O
freely	O
diffuse	O
into	O
the	O
lipidic	O
bilayer31	O
.	O

It	O
is	O
known	O
that	O
band	B-GP
3	I-GP
pass	O
through	O
molecular	O
conformation	O
modifications	O
during	O
initial	O
immune	O
responses	O
to	O
malaria	B-DS
parasites	O
,	O
which	O
leads	O
to	O
exposure	O
of	O
new	O
epitopes20	O
,	O
21	O
.	O

Thus	O
,	O
since	O
these	O
modifications	O
in	O
band	B-GP
3	I-GP
are	O
associated	O
to	O
hemichrome	O
deposition	O
and	O
reactive	O
oxygen	O
species	O
generation	O
,	O
they	O
may	O
persist	O
after	O
parasite	O
clearance	O
giving	O
rise	O
to	O
changes	O
in	O
chloride	B-GP
/	I-GP
bicarbonate	I-GP
transporter	I-GP
activity21	O
,	O
thereby	O
affecting	O
RBC	O
CO2	O
transport	O
and	O
contributing	O
to	O
anemia	B-DS
.	O

Also	O
,	O
possibility	O
of	O
enzymatic	O
hydrolysis	O
of	O
spectrin	B-GP
may	O
be	O
taken	O
into	O
account32	O
.	O

Several	O
mechanisms	O
are	O
involved	O
in	O
the	O
production	O
of	O
self	O
-	O
reactive	O
antibodies	B-GP
in	O
malaria	B-DS
including	O
polyclonal	O
activation	O
of	O
B	O
cells	O
induced	O
by	O
parasite	O
antigens33	O
,	O
dysregulation	O
of	O
B	O
lymphocytes33	O
,	O
34	O
and	O
stimulation	O
of	O
specific	O
B	O
lymphocytes	O
by	O
molecular	O
mimicry35	O
.	O

To	O
investigate	O
whether	O
molecular	O
mimicry	O
is	O
underlying	O
vivax	B-DS
malaria	I-DS
-	O
associated	O
anemia	B-DS
,	O
we	O
identified	O
P	B-OG
.	I-OG
vivax	I-OG
proteins	O
that	O
share	O
homology	O
at	O
the	O
molecular	O
level	O
with	O
proteins	O
from	O
human	B-OG
RBCs	O
using	O
bioinformatics	O
tools	O
.	O

Homologous	O
regions	O
of	O
primary	O
structure	O
were	O
found	O
between	O
P	B-OG
.	I-OG
vivax	I-OG
and	O
human	B-OG
spectrin	B-GP
,	O
a	O
result	O
that	O
may	O
explain	O
the	O
increase	O
in	O
levels	O
of	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
detected	O
by	O
ELISA	O
in	O
plasma	O
of	O
patients	O
infected	O
by	O
P	B-OG
.	I-OG
vivax	I-OG
.	O

In	O
line	O
with	O
this	O
idea	O
is	O
the	O
study	O
by	O
Berti	O
et	O
al	O
.	O
36	O
,	O
who	O
reported	O
that	O
a	O
surge	O
in	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
following	O
the	O
intraperitoneal	O
injection	O
of	O
spectrin	B-GP
in	O
rats	B-OG
affected	O
the	O
homeostasis	O
of	O
RBC	O
by	O
accelerating	O
their	O
elimination	O
and	O
stimulating	O
erythropoiesis	O
.	O

It	O
is	O
possible	O
that	O
host	O
spectrin	B-GP
and	O
spectrin	B-GP
-	I-GP
homologous	I-GP
proteins	I-GP
derived	O
from	O
the	O
parasite	O
trigger	O
the	O
generation	O
of	O
autoantibodies	B-GP
that	O
mediate	O
the	O
destruction	O
of	O
nRBCs	O
.	O

This	O
anemic	O
scenario	O
leads	O
to	O
increased	O
erythropoiesis	O
,	O
which	O
,	O
in	O
turn	O
,	O
favours	O
reticulocyte	O
infection	B-DS
by	O
P	B-OG
.	I-OG
vivax	I-OG
,	O
thus	O
supporting	O
molecular	O
mimicry	O
as	O
an	O
advantageous	O
host	O
-	O
parasite	O
adaptation	O
.	O

Although	O
little	O
is	O
known	O
about	O
molecular	O
mimicry	O
in	O
P	B-OG
.	I-OG
vivax	I-OG
,	O
this	O
mechanism	O
has	O
been	O
proposed	O
for	O
other	O
Plasmodium	B-OG
species37	O
.	O

The	O
protein	O
candidates	O
include	O
:	O
P	B-OG
.	I-OG
falciparum	I-OG
merozoite	B-GP
surface	I-GP
protein	I-GP
1	I-GP
(	O
PfMSP	B-GP
-	I-GP
1	I-GP
),	O
which	O
has	O
human	B-OG
epidermal	B-GP
growth	I-GP
factor	I-GP
-	O
like	O
motifs38	O
;	O
the	O
P	B-OG
.	I-OG
falciparum	I-OG
translationally	B-GP
controlled	I-GP
tumor	I-GP
protein	I-GP
(	O
PfTCTP	B-GP
),	O
which	O
is	O
homologous	O
to	O
the	O
human	B-OG
histamine	B-GP
releasing	I-GP
factor39	I-GP
;	O
and	O
P	B-OG
.	I-OG
falciparum	I-OG
erythrocyte	B-GP
membrane	I-GP
protein	I-GP
1	I-GP
(	O
PfEMP1	B-GP
),	O
which	O
shares	O
motifs	O
with	O
human	B-OG
vitronectin40	B-GP
.	O

Phylogenetic	O
analysis	O
comparing	O
different	O
Plasmodium	B-OG
species	O
showed	O
two	O
groups	O
of	O
spectrin	B-GP
-	I-GP
like	I-GP
proteins	I-GP
,	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
as	O
an	O
outlier	O
.	O

The	O
C	O
-	O
terminus	O
of	O
spectrin	B-GP
-	O
like	O
Plasmodium	B-OG
orthologue	O
proteins	O
are	O
highly	O
conserved	O
(	O
Fig	O
.	O
5	O
).	O

To	O
find	O
a	O
possible	O
biological	O
relevance	O
of	O
spectrin	B-GP
,	O
putative	O
domains	O
were	O
predicted	O
and	O
,	O
curiously	O
,	O
the	O
C	O
-	O
terminus	O
conserved	O
region	O
was	O
predicted	O
to	O
be	O
a	O
pleckstrin	B-GP
homology	O
-	O
like	O
domain	O
(	O
PH	O
-	O
like	O
).	O
Although	O
such	O
predictions	O
do	O
not	O
define	O
the	O
protein	O
function	O
,	O
it	O
is	O
known	O
that	O
increased	O
expression	O
of	O
this	O
domain	O
family	O
in	O
humans	B-OG
is	O
associated	O
with	O
the	O
presence	O
of	O
anemia41	B-DS
.	O

Moreover	O
,	O
it	O
has	O
been	O
shown	O
that	O
pleckstrin	B-GP
-	I-GP
2	I-GP
,	O
which	O
contains	O
two	O
PH	O
domains	O
,	O
plays	O
a	O
critical	O
role	O
in	O
erythropoiesis42	O
.	O

Altogether	O
,	O
these	O
data	O
may	O
explain	O
how	O
molecular	O
mimicry	O
of	O
spectrin	B-GP
relates	O
with	O
the	O
anemic	O
status	O
induced	O
by	O
Plasmodium	B-DS
infection	I-DS
.	O

Since	O
spectrin	B-GP
is	O
present	O
on	O
the	O
intracellular	O
side	O
of	O
the	O
erythrocyte	O
membrane	O
,	O
it	O
remains	O
unclear	O
how	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
bind	O
to	O
a	O
cytoplasmic	O
protein	O
.	O

Although	O
we	O
do	O
not	O
have	O
an	O
explanation	O
for	O
such	O
observation	O
,	O
this	O
is	O
not	O
the	O
first	O
time	O
that	O
immunoglobulins	B-GP
directed	O
towards	O
an	O
intracellular	O
antigen	O
have	O
been	O
detected	O
.	O

The	O
reaction	O
of	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
with	O
RBCs	O
has	O
been	O
previously	O
described	O
by	O
studies	O
investigating	O
the	O
clearance	O
of	O
aged	O
erythrocytes43	O
,	O
44	O
.	O

We	O
suggest	O
that	O
during	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
,	O
the	O
destruction	O
of	O
erythrocytes	O
releases	O
spectrin	B-GP
in	O
the	O
plasma	O
,	O
where	O
it	O
could	O
bind	O
to	O
circulating	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
,	O
thereby	O
eliciting	O
complement	O
deposition	O
onto	O
these	O
complexes	O
.	O

RBC	O
engulfment	O
by	O
macrophages	O
is	O
affected	O
by	O
cell	O
stiffness	O
and	O
molecular	O
interactions	O
in	O
cell	O
surface45	O
.	O

Therefore	O
,	O
deposition	O
of	O
those	O
immunocomplexes	O
on	O
the	O
surface	O
of	O
nRBCs	O
through	O
the	O
complement	B-GP
receptor	I-GP
1	I-GP
(	O
CR1	B-GP
)	O
could	O
decrease	O
nRBCs	O
deformability	O
thus	O
predisposing	O
them	O
to	O
clearance	O
by	O
phagocytes	O
and	O
contributing	O
to	O
anemia	B-DS
in	O
vivax	B-DS
malaria	I-DS
.	O

Immune	O
response	O
against	O
cytoskeletal	B-GP
proteins	I-GP
may	O
contribute	O
to	O
falciparum	B-DS
malaria46	I-DS
,	O
47	O
.	O

Nevertheless	O
,	O
no	O
studies	O
are	O
available	O
for	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
associated	O
anemia	B-DS
,	O
but	O
since	O
our	O
immunoproteomic	O
data	O
suggest	O
the	O
presence	O
of	O
antibodies	B-GP
for	O
band	B-GP
3	I-GP
and	O
for	O
associated	O
cytoskeletal	B-GP
proteins	I-GP
,	O
and	O
also	O
considering	O
that	O
antibodies	B-GP
for	O
those	O
proteins	O
are	O
involved	O
in	O
RBC	O
clearance29	O
,	O
further	O
investigation	O
of	O
contribution	O
of	O
these	O
antibodies	B-GP
to	O
the	O
pathogenesis	O
of	O
vivax	B-OG
-	O
associated	O
anemia	B-DS
is	O
necessary	O
.	O

Methods	O

Ethics	O
statement	O

This	O
study	O
was	O
conducted	O
according	O
to	O
the	O
principles	O
expressed	O
in	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
National	O
Information	O
System	O
on	O
Research	O
Ethics	O
Involving	O
Human	B-OG
Beings	O
(	O
SISNEP	O
-	O
CAAE01496013	O
.	O
8	O
.	O
0000	O
.	O
5149	O
).	O

All	O
healthy	O
donors	O
and	O
patients	O
were	O
anonymized	O
,	O
and	O
they	O
provided	O
written	O
informed	O
consent	O
for	O
the	O
collection	O
of	O
samples	O
and	O
subsequent	O
analysis	O
.	O

Plasma	O
samples	O

Blood	O
samples	O
were	O
collected	O
between	O
February	O
2006	O
and	O
January	O
2008	O
from	O
adults	O
with	O
patent	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
who	O
attended	O
and	O
were	O
diagnosed	O
at	O
the	O
Hospital	O
Universitário	O
Júlio	O
Muller	O
,	O
in	O
Cuiabá	O
(	O
Mato	O
Grosso	O
State	O
,	O
Brazil	O
).	O
P	B-OG
.	I-OG
vivax	I-OG
mono	O
-	O
infections	B-DS
were	O
diagnosed	O
by	O
thick	O
blood	O
smear	O
and	O
further	O
confirmed	O
by	O
nested	O
PCR	O
amplification	O
of	O
species	O
-	O
specific	O
sequence	O
of	O
the	O
18s	O
SSU	O
rRNA	O
gene	O
of	O
Plasmodium	B-OG
,	O
as	O
previously	O
described48	O
.	O

The	O
clinical	O
history	O
and	O
demographic	O
profile	O
were	O
obtained	O
from	O
all	O
the	O
subjects	O
.	O

Individuals	O
were	O
assigned	O
according	O
to	O
the	O
results	O
of	O
complete	O
blood	O
count	O
into	O
two	O
groups	O
:	O
(	O
i	O
)	O
malaria	B-DS
patients	O
without	O
anemia	B-DS
(	O
n	O
=	O
24	O
)	O
and	O
(	O
ii	O
)	O
malaria	B-DS
patients	O
with	O
anemia	B-DS
(	O
n	O
=	O
24	O
)	O
(	O
Table	O
3	O
).	O

Anemia	B-DS
was	O
set	O
as	O
hemoglobin	B-GP
levels	O
less	O
than	O
or	O
equal	O
to	O
11	O
g	O
/	O
dL	O
and	O
only	O
patients	O
with	O
normocytic	O
(	O
mean	O
corpuscular	O
volume	O
80	O
–	O
96	O
fL	O
)	O
and	O
normochromic	O
(	O
mean	O
corpuscular	O
hemoglobin	B-GP
concentration	O
32	O
–	O
36	O
g	O
/	O
dL	O
)	O
anemia	B-DS
were	O
included	O
.	O

Patients	O
presenting	O
severe	B-DS
malnutrition	I-DS
or	O
infections	B-DS
such	O
as	O
HIV	B-OG
or	O
hepatitis	B-DS
were	O
excluded	O
from	O
the	O
study	O
.	O

As	O
control	O
,	O
we	O
included	O
plasma	O
from	O
healthy	O
volunteers	O
who	O
had	O
never	O
been	O
exposed	O
to	O
malaria	B-DS
(	O
n	O
=	O
8	O
).	O
Table	O
3Baseline	O
characteristics	O
of	O
the	O
study	O
population	O
.	O
CharacteristicP	O
.	O
vivax	B-OG
anemic	O
(	O
n	O
=	O
24	O
)	O
P	B-OG
.	I-OG
vivax	I-OG
non	O
-	O
anemic	O
(	O
n	O
=	O
24	O
)	O
p	O
value	O
(	O
Mann	O
-	O
Whitney	O
test	O
)	O
Age	O
(	O
years	O
)	O
29	O
.	O
5	O
[	O
27	O
.	O
7	O
–	O
41	O
.	O
2	O
]	O
30	O
.	O
0	O
[	O
24	O
.	O
0	O
–	O
42	O
.	O
0	O
]	O
0	O
.	O
8954Number	O
of	O
malaria	B-DS
previous	O
episodes2	O
[	O
1	O
–	O
4	O
]	O
3	O
[	O
0	O
–	O
10	O
]	O
0	O
.	O
8895Parasitemia	B-DS
(	O
parasites	O
/	O
µL	O
)	O
7	O
,	O
275	O
[	O
2	O
,	O
418	O
–	O
12	O
,	O
331	O
]	O
2	O
,	O
375	O
[	O
7	O
,	O
000	O
–	O
16	O
,	O
500	O
]	O
0	O
.	O
0517Hemoglobin	O
(	O
g	O
/	O
dL	O
)	O
9	O
.	O
7	O
[	O
8	O
.	O
4	O
–	O
10	O
.	O
1	O
]	O
16	O
.	O
1	O
[	O
15	O
.	O
4	O
–	O
16	O
.	O
8	O
]<	O
0	O
.	O
0001Hematocrit	O
(%)	O
28	O
.	O
0	O
[	O
25	O
.	O
0	O
–	O
29	O
.	O
4	O
]	O
46	O
.	O
1	O
[	O
45	O
.	O
4	O
–	O
48	O
.	O
08	O
]<	O
0	O
.	O
0001Platelets	O
(	O
cells	O
/	O
mm3	O
)	O
101	O
,	O
000	O
[	O
69	O
,	O
000	O
–	O
126	O
,	O
000	O
]	O
160	O
,	O
500	O
[	O
112	O
,	O
750	O
–	O
193	O
,	O
250	O
]	O
0	O
.	O
0106Leucocytes	O
(	O
cells	O
/	O
mm3	O
)	O
4	O
,	O
900	O
[	O
3	O
,	O
700	O
–	O
6	O
,	O
000	O
]	O
5	O
,	O
390	O
[	O
4	O
,	O
633	O
–	O
6	O
,	O
313	O
]	O
0	O
.	O
2930Values	O
are	O
shown	O
as	O
median	O
and	O
interquartile	O
ranges	O
.	O

For	O
the	O
immunoproteomics	O
approach	O
,	O
we	O
prepared	O
a	O
pool	O
containing	O
plasma	O
from	O
seven	O
individuals	O
for	O
each	O
studied	O
group	O
.	O

These	O
individuals	O
were	O
those	O
who	O
presented	O
median	O
levels	O
of	O
IgG	B-GP
against	O
nRBCs	O
detected	O
by	O
ELISA	O
as	O
it	O
will	O
be	O
described	O
below	O
in	O
section	O
3	O
.	O
4	O
.	O

It	O
is	O
important	O
to	O
mention	O
that	O
blood	O
samples	O
from	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
infected	O
patients	O
were	O
collected	O
on	O
the	O
onset	O
of	O
diagnosis	O
,	O
during	O
the	O
acute	O
phase	O
of	O
infection	B-DS
and	O
before	O
starting	O
treatment	O
.	O

The	O
treatment	O
consisted	O
in	O
chloroquine	O
(	O
150	O
mg	O
/	O
day	O
,	O
3	O
days	O
)	O
associated	O
with	O
primaquine	O
(	O
15	O
mg	O
/	O
day	O
,	O
7	O
days	O
)	O
at	O
doses	O
calculated	O
per	O
kilogram	O
of	O
weight	O
,	O
as	O
proposed	O
by	O
the	O
Brazilian	O
Ministry	O
of	O
Health	O
guidelines	O
for	O
P	B-OG
.	I-OG
vivax	I-OG
uncomplicated	O
malaria	B-DS
therapy	O
.	O

RBC	O
extract	O
preparation	O

Erythrocyte	O
membrane	O
extract	O
was	O
prepared	O
with	O
RBCs	O
obtained	O
from	O
a	O
healthy	O
O	O
+	O
blood	O
type	O
donor	O
after	O
separation	O
using	O
Ficoll	O
-	O
Paque	O
Plus	O
(	O
GE	O
Healthcare	O
,	O
Pittsburgh	O
,	O
PA	O
).	O

Hemoglobin	B-GP
-	O
free	O
erythrocyte	O
ghosts	O
were	O
obtained	O
by	O
hypotonic	O
lysis	O
as	O
previously	O
described49	O
.	O

Membrane	B-GP
proteins	I-GP
were	O
solubilized	O
in	O
8	O
M	O
urea	O
,	O
2	O
M	O
thiourea	O
,	O
4	O
%	O
w	O
/	O
v	O
CHAPS	O
,	O
0	O
.	O
0025	O
%	O
bromophenol	O
blue	O
,	O
65	O
mM	O
DTT	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
),	O
1	O
%	O
v	O
/	O
v	O
BioLyte	O
3	O
–	O
10	O
100X	O
buffer	O
(	O
Bio	O
-	O
Rad	O
)	O
and	O
precipitated	O
using	O
2D	O
Clean	O
-	O
Up	O
Kit	O
(	O
GE	O
Healthcare	O
,	O
Pittsburgh	O
,	O
PA	O
).	O

Protein	O
concentration	O
was	O
estimated	O
using	O
Bradford	O
assay	O
.	O

Detection	O
of	O
IgG	B-GP
against	O
nRBCs	O
proteins	O

Serum	O
levels	O
of	O
IgG	B-GP
against	O
nRBCs	O
extracts	O
were	O
determined	O
by	O
ELISA	O
.	O

Briefly	O
,	O
each	O
well	O
of	O
a	O
96	O
-	O
well	O
flat	O
-	O
bottomed	O
polystyrene	O
microplate	O
(	O
Corning	O
Incorporation	O
,	O
Corning	O
,	O
NY	O
,	O
USA	O
)	O
was	O
coated	O
with	O
0	O
.	O
1	O
ng	O
of	O
RBC	O
protein	O
extract	O
in	O
0	O
.	O
1	O
M	O
carbonate	O
buffer	O
,	O
pH	O
9	O
.	O
6	O
,	O
and	O
then	O
incubated	O
overnight	O
at	O
4	O
°	O
C	O
.	O

After	O
five	O
washes	O
with	O
PBS	O
containing	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
bovine	O
serum	O
albumin	B-GP
(	O
BSA	B-GP
),	O
the	O
plate	O
was	O
blocked	O
with	O
nonfat	O
powdered	O
milk	O
for	O
two	O
hours	O
at	O
37	O
°	O
C	O
.	O

Next	O
,	O
plates	O
were	O
washed	O
and	O
incubated	O
,	O
in	O
duplicate	O
,	O
with	O
serum	O
samples	O
diluted	O
1	O
:	O
200	O
in	O
PBS	O
/	O
BSA	B-GP
for	O
2	O
hours	O
at	O
3	O
°	O
C	O
.	O

Wells	O
were	O
rewashed	O
and	O
incubated	O
with	O
horseradish	B-OG
peroxidase	B-GP
conjugated	O
polyclonal	O
anti	O
-	O
human	B-OG
IgG	B-GP
diluted	O
1	O
:	O
8000	O
in	O
PBS	O
/	O
BSA	B-GP
for	O
90	O
minutes	O
at	O
37	O
°	O
C	O
.	O

Finally	O
,	O
the	O
plates	O
were	O
washed	O
again	O
,	O
and	O
the	O
reaction	O
was	O
revealed	O
using	O
0	O
.	O
5	O
mg	O
/	O
mL	O
o	O
-	O
phenylenediamine	O
dihydrochloride	O
substrate	O
in	O
0	O
.	O
05	O
M	O
phosphate	O
-	O
citrate	O
buffer	O
,	O
pH	O
5	O
.	O
0	O
.	O

The	O
reaction	O
was	O
stopped	O
with	O
3M	O
H2SO4	O
.	O

Optical	O
density	O
(	O
OD492	O
nm	O
)	O
was	O
determined	O
in	O
a	O
Spectra	O
Max	O
250	O
microplate	O
reader	O
(	O
Molecular	O
Devices	O
,	O
San	O
Jose	O
,	O
CA	O
).	O

The	O
levels	O
of	O
specific	O
IgG	B-GP
were	O
expressed	O
as	O
OD492nm	O
.	O

Two	O
-	O
dimensional	O
Western	O
blotting	O
and	O
protein	O
identification	O

RBC	O
proteins	O
(	O
100	O
µg	O
)	O
were	O
separated	O
by	O
2D	O
gel	O
electrophoresis	O
.	O

RBC	O
extract	O
was	O
loaded	O
onto	O
immobilized	O
pH	O
gradient	O
(	O
IPG	O
)	O
strips	O
(	O
7	O
cm	O
,	O
pH	O
4	O
–	O
7	O
;	O
Bio	O
-	O
Rad	O
)	O
and	O
subjected	O
to	O
isoelectric	O
focusing	O
.	O

Next	O
,	O
RBC	O
proteins	O
were	O
reduced	O
,	O
alkylated	O
and	O
separated	O
on	O
12	O
%	O
SDS	O
-	O
polyacrylamide	O
(	O
SDS	O
-	O
PAGE	O
)	O
gel50	O
.	O

To	O
identify	O
nRBCs	O
antigens	O
recognized	O
by	O
antibodies	B-GP
from	O
the	O
studied	O
groups	O
,	O
two	O
2D	O
-	O
SDS	O
-	O
PAGE	O
were	O
performed	O
in	O
parallel	O
to	O
each	O
group	O
.	O

The	O
preparative	O
2D	O
-	O
SDS	O
-	O
PAGE	O
gels	O
were	O
stained	O
with	O
Coomassie	O
brilliant	O
blue	O
G	O
-	O
250	O
(	O
BioRad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
).	O

The	O
remaining	O
2D	O
-	O
SDS	O
-	O
PAGE	O
gels	O
were	O
electroblotted	O
onto	O
PVDF	O
membranes	O
(	O
BioRad	O
)	O
in	O
transfer	O
buffer	O
(	O
25	O
mM	O
Tris	O
-	O
Base	O
,	O
192	O
mM	O
glycine	O
,	O
20	O
%	O
methanol	O
,	O
pH	O
8	O
.	O
3	O
).	O

Each	O
membrane	O
was	O
probed	O
with	O
each	O
serum	O
pool	O
diluted	O
1	O
:	O
200	O
in	O
TBS	O
(	O
20	O
mM	O
Tris	O
-	O
HCl	O
,	O
500	O
mM	O
NaCl	O
pH	O
7	O
.	O
5	O
)	O
containing	O
0	O
.	O
05	O
%	O
Tween	O
-	O
20	O
and	O
1	O
%	O
BSA	B-GP
.	O

HRP	B-GP
-	O
conjugated	O
goat	B-OG
anti	O
-	O
human	B-OG
IgG	B-GP
(	O
1	O
:	O
6000	O
)	O
and	O
a	O
chemiluminescence	O
-	O
based	O
kit	O
(	O
ECL	O
;	O
GE	O
Healthcare	O
)	O
was	O
used	O
to	O
detect	O
the	O
immunoreactive	O
spots	O
.	O

Three	O
immunoblots	O
were	O
performed	O
for	O
each	O
serum	O
group	O
.	O

After	O
image	O
analysis	O
(	O
Image	O
Master	O
2D	O
Platinum	O
7	O
.	O
0	O
,	O
GE	O
Healthcare	O
),	O
all	O
immunoreactive	O
spots	O
that	O
matched	O
to	O
their	O
homologues	O
in	O
2D	O
-	O
SDS	O
-	O
PAGE	O
gels	O
were	O
excised	O
,	O
distained	O
and	O
digested	O
with	O
trypsin	B-GP
(	O
Trypsin	O
Gold	O
,	O
Mass	O
Spectrometry	O
Grade	O
,	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
).	O

The	O
tryptic	O
peptides	O
obtained	O
were	O
extracted	O
and	O
had	O
their	O
volume	O
decreased	O
under	O
reduced	O
pressure	O
.	O

After	O
a	O
desalting	O
step	O
(	O
C18	O
-	O
µZipTip	O
,	O
Merck	O
-	O
Millipore	O
,	O
Bilerica	O
,	O
USA	O
),	O
the	O
peptides	O
were	O
dried	O
,	O
suspended	O
in	O
ultrapure	O
water	O
,	O
spotted	O
onto	O
a	O
MALDI	O
target	O
plate	O
(	O
BrukerDaltonics	O
,	O
Bilerica	O
,	O
MA	O
,	O
USA	O
)	O
and	O
analysed	O
using	O
MALDI	O
-	O
ToF	O
and	O
MALDI	O
-	O
ToF	O
/	O
ToF	O
(	O
Autoflex	O
Speed	O
or	O
Ultraflex	O
III	O
,	O
BrukerDaltonics	O
).	O

MS	O
and	O
MS	O
/	O
MS	O
spectra	O
were	O
acquired	O
using	O
Flex	O
Control	O
2	O
.	O
0	O
(	O
Bruker	O
Daltonics	O
).	O

The	O
external	O
calibration	O
MS	O
mode	O
was	O
performed	O
using	O
Peptide	O
Calibration	O
Standard	O
II	O
(	O
Bruker	O
Daltonics	O
)	O
according	O
to	O
manufacturer	O
instruction	O
.	O

Mass	O
analysis	O
ranged	O
from	O
m	O
/	O
z	O
=	O
500	O
to	O
m	O
/	O
z	O
=	O
4000	O
.	O

The	O
ToF	O
operation	O
was	O
conducted	O
in	O
the	O
reflected	O
mode	O
.	O

All	O
mass	O
spectra	O
were	O
obtained	O
in	O
the	O
positive	O
ion	O
reflector	O
mode	O
,	O
using	O
α	O
-	O
cyano	O
-	O
4	O
-	O
hydroxycinnamic	O
acid	O
as	O
matrix	O
.	O

For	O
the	O
calibration	O
of	O
the	O
MS	O
/	O
MS	O
mode	O
,	O
parent	O
ions	O
from	O
each	O
of	O
those	O
peptides	O
contained	O
in	O
the	O
calibration	O
mixture	O
were	O
selected	O
and	O
fragmented	O
.	O

The	O
fragmentation	O
was	O
conducted	O
using	O
LIFT	O
™	O
technology51	O
.	O

MS	O
/	O
MS	O
spectra	O
were	O
also	O
obtained	O
in	O
the	O
positive	O
mode	O
.	O

Theoretical	O
values	O
of	O
[	O
M	O
+	O
H	O
]+	O
for	O
each	O
precursor	O
ion	O
were	O
calculated	O
by	O
“	O
Isotope	O
-	O
MS	O
”	O
Protein	O
Prospector	O
tool	O
(	O
http	O
://	O
prospector	O
.	O
ucsf	O
.	O
edu	O
/	O
prospector	O
/	O
mshome	O
.	O
htm	O
).	O

Mass	O
spectra	O
were	O
edited	O
and	O
analysed	O
using	O
Flex	O
Analysis	O
3	O
.	O
3	O
and	O
Biotools	O
3	O
.	O
0	O
(	O
Bruker	O
Daltonics	O
).	O

The	O
lists	O
containing	O
experimentally	O
obtained	O
m	O
/	O
z	O
ratios	O
were	O
compared	O
to	O
theoretical	O
values	O
generated	O
by	O
in	O
silico	O
digestion	O
of	O
all	O
human	B-OG
protein	O
sequences	O
deposited	O
in	O
SwissProt	O
and	O
NCBInr	O
protein	O
databases	O
through	O
Biotools	O
v	O
program	O
.	O

3	O
.	O
0	O
(	O
Bruker	O
Daltonics	O
)	O
coupled	O
to	O
the	O
Mascot	O
v	O
.	O

2	O
.	O
1	O
and	O
2	O
.	O
2	O
.	O

Protein	O
identification	O
was	O
assigned	O
by	O
peptide	O
mass	O
fingerprint	O
(	O
PMF	O
)	O
and	O
by	O
MS	O
/	O
MS	O
Ion	O
Search	O
using	O
the	O
search	O
program	O
Mascot	O
.	O

Searches	O
were	O
performed	O
firstly	O
against	O
the	O
SwissProt	O
database	O
and	O
when	O
it	O
did	O
not	O
lead	O
to	O
identification	O
,	O
they	O
were	O
confronted	O
against	O
the	O
NCBInr	O
.	O

To	O
avoid	O
random	O
matches	O
,	O
identification	O
was	O
considered	O
valid	O
only	O
for	O
samples	O
whose	O
scores	O
exceeded	O
the	O
identity	O
or	O
extensive	O
homology	O
threshold	O
value	O
that	O
was	O
calculated	O
by	O
MASCOT	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

To	O
confirm	O
the	O
identifications	O
and	O
to	O
identify	O
the	O
proteins	O
that	O
did	O
not	O
present	O
a	O
significant	O
score	O
in	O
those	O
analyses	O
,	O
MS	O
/	O
MS	O
spectra	O
were	O
interpreted	O
by	O
manual	O
inspection	O
taking	O
into	O
consideration	O
the	O
widely	O
accepted	O
mechanisms	O
for	O
the	O
fragmentation	O
of	O
peptides	O
as	O
well	O
as	O
the	O
mechanically	O
favoured	O
or	O
disfavoured	O
cleavage	O
events52	O
,	O
53	O
.	O

Preparation	O
of	O
RBC	O
antigens	O

Band	B-GP
3	I-GP
protein	O

To	O
separate	O
erythrocytes	O
from	O
leucocytes	O
,	O
freshly	O
drawn	O
blood	O
collected	O
in	O
heparinized	O
tube	O
was	O
layered	O
on	O
Histopaque	O
and	O
centrifuged	O
at	O
1000	O
g	O
for	O
20	O
min	O
.	O

Packed	O
erythrocytes	O
were	O
washed	O
three	O
times	O
with	O
PBS	O
.	O

Hemoglobin	B-GP
-	O
free	O
erythrocyte	O
membranes	O
(	O
ghosts	O
)	O
were	O
prepared	O
by	O
osmotic	O
lysis	O
of	O
the	O
washed	O
erythrocyte	O
.	O

The	O
washed	O
cells	O
were	O
hemolyzed	O
in	O
ten	O
volumes	O
of	O
ice	O
-	O
cold	O
5	O
mM	O
phosphate	O
buffer	O
(	O
pH	O
8	O
.	O
0	O
)	O
containing	O
0	O
.	O
1	O
mM	O
PMSF	O
and	O
incubated	O
30	O
min	O
at	O
4	O
ºC	O
.	O

The	O
ghosts	O
were	O
centrifuged	O
at	O
20	O
,	O
000	O
g	O
for	O
30	O
min	O
.	O

The	O
supernatant	O
was	O
carefully	O
aspirated	O
without	O
disturbing	O
ghost	O
pellet	O
.	O

This	O
procedure	O
was	O
repeated	O
until	O
membranes	O
were	O
free	O
of	O
hemoglobin	B-GP
and	O
the	O
pellet	O
become	O
milky	O
white	O
.	O

Then	O
,	O
the	O
peripheral	O
proteins	O
were	O
stripped	O
from	O
membrane	O
by	O
suspending	O
it	O
in	O
ten	O
volumes	O
of	O
ice	O
-	O
cold	O
2	O
mM	O
EDTA	O
(	O
pH	O
12	O
.	O
0	O
).	O

Immediately	O
after	O
dilution	O
,	O
the	O
membrane	O
was	O
pelleted	O
by	O
centrifugation	O
at	O
48	O
,	O
000	O
g	O
for	O
30	O
min	O
at	O
4	O
ºC	O
and	O
washed	O
three	O
times	O
with	O
5	O
mM	O
phosphate	O
buffer	O
,	O
(	O
pH	O
8	O
.	O
0	O
).	O

The	O
stripped	O
membrane	O
(	O
15	O
–	O
20	O
mg	O
protein	O
/	O
mL	O
)	O
was	O
resuspended	O
in	O
5	O
mM	O
phosphate	O
buffer	O
,	O
pH	O
8	O
.	O
0	O
,	O
and	O
five	O
volumes	O
of	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
C12E8	O
in	O
5mM	O
phosphate	O
buffer	O
,	O
pH	O
8	O
.	O
0	O
was	O
added	O
.	O

This	O
mixture	O
was	O
incubated	O
at	O
4	O
ºC	O
for	O
20	O
min	O
and	O
centrifuged	O
at	O
48	O
,	O
000	O
g	O
for	O
2	O
h	O
at	O
4	O
ºC	O
.	O

Band	B-GP
3	I-GP
protein	O
was	O
purified	O
by	O
affinity	O
chromatography	O
on	O
aminoethyl	O
-	O
agarose	O
resin	O
(	O
ABT	O
beads	O
,	O
Madrid	O
,	O
Spain	O
).	O

Amino	O
ethyl	O
-	O
agarose	O
was	O
packed	O
in	O
column	O
and	O
equilibrated	O
with	O
0	O
.	O
1	O
%	O
C12E8	O
,	O
5	O
mM	O
phosphate	O
buffer	O
(	O
pH	O
8	O
.	O
0	O
).	O

The	O
solubilized	O
membrane	B-GP
protein	I-GP
was	O
loaded	O
onto	O
the	O
column	O
and	O
washed	O
with	O
one	O
bed	O
volume	O
of	O
0	O
.	O
1	O
%	O
C12E8	O
5	O
mM	O
phosphate	O
buffer	O
(	O
pH8	O
.	O
0	O
).	O

A	O
linear	O
gradient	O
of	O
0	O
–	O
300	O
NaCl	O
in	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
C12E8	O
in	O
5	O
mM	O
phosphate	O
buffer	O
,	O
pH	O
8	O
.	O
0	O
,	O
of	O
ten	O
bed	O
volume	O
were	O
applied	O
to	O
column	O
.	O

Band	B-GP
3	I-GP
was	O
eluted	O
at	O
100	O
mM	O
NaCl	O
and	O
collected	O
in	O
fractions	O
of	O
1	O
mL	O
in	O
sterile	O
tubes	O
.	O

Concentration	O
was	O
determined	O
by	O
spectrophotometry	O
and	O
purity	O
of	O
the	O
preparation	O
was	O
checked	O
by	O
10	O
%	O
SDS	O
-	O
PAGE	O
.	O

Eluted	O
protein	O
was	O
divided	O
in	O
fractions	O
at	O
1	O
mg	O
/	O
mL	O
in	O
5	O
mM	O
phosphate	O
buffer	O
and	O
lyophilized	O
overnight	O
.	O

Spectrin	B-GP
protein	O

Spectrin	B-GP
was	O
extracted	O
from	O
RBCs	O
as	O
previously	O
described	O
with	O
some	O
modifications54	O
–	O
56	O
.	O

Briefly	O
,	O
blood	O
was	O
collected	O
and	O
centrifuged	O
at	O
1000	O
g	O
,	O
for	O
20	O
minutes	O
at	O
4	O
ºC	O
in	O
order	O
to	O
remove	O
plasma	O
and	O
buffy	O
coat	O
.	O

Packed	O
RBCs	O
were	O
washed	O
three	O
times	O
with	O
20	O
volumes	O
of	O
5	O
mM	O
sodium	O
phosphate	O
buffer	O
(	O
pH	O
8	O
.	O
0	O
)	O
containing	O
0	O
.	O
95	O
%	O
(	O
w	O
/	O
v	O
)	O
NaCl	O
and	O
the	O
cells	O
were	O
collected	O
after	O
each	O
wash	O
procedure	O
by	O
centrifugation	O
at	O
4000	O
g	O
for	O
10	O
minutes	O
.	O

The	O
cells	O
were	O
then	O
hemolyzed	O
in	O
5	O
mM	O
sodium	O
phosphate	O
,	O
pH	O
8	O
.	O
0	O
,	O
and	O
the	O
membranes	O
collected	O
by	O
centrifugation	O
at	O
37000	O
g	O
for	O
15	O
min	O
.	O

Membranes	O
were	O
washed	O
in	O
the	O
same	O
buffer	O
until	O
a	O
pale	O
yellow	O
colour	O
appears	O
.	O

The	O
supernatant	O
was	O
removed	O
,	O
and	O
the	O
pellet	O
was	O
suspended	O
in	O
an	O
equal	O
volume	O
of	O
spectrin	B-GP
removal	O
buffer	O
(	O
0	O
.	O
2	O
mM	O
sodium	O
phosphate	O
,	O
0	O
.	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
2	O
mM	O
dithiothreitol	O
(	O
DTT	O
),	O
20	O
µg	O
/	O
mL	O
phenylmethyl	O
sulfonyl	O
fluoride	O
(	O
PMSF	O
),	O
pH	O
8	O
.	O
0	O
,	O
37	O
ºC	O
for	O
20	O
–	O
60	O
minutes	O
for	O
the	O
release	O
of	O
the	O
dimeric	O
spectrin	B-GP
.	O

The	O
tetrameric	O
spectrin	B-GP
was	O
purified	O
with	O
the	O
same	O
protocol	O
but	O
the	O
incubation	O
was	O
performed	O
at	O
4	O
ºC	O
.	O

Membranes	O
were	O
removed	O
from	O
the	O
incubated	O
sample	O
by	O
centrifugation	O
at	O
27000	O
g	O
for	O
15	O
minutes	O
,	O
and	O
the	O
supernatant	O
was	O
concentrated	O
by	O
dialysis	O
against	O
spectrin	B-GP
removal	O
buffer	O
.	O

Then	O
,	O
vesicles	O
were	O
clarified	O
by	O
centrifugation	O
(	O
27000	O
X	O
g	O
,	O
15	O
minutes	O
)	O
and	O
both	O
dimeric	O
and	O
tetrameric	O
spectrins	B-GP
were	O
purified	O
after	O
concentration	O
by	O
30	O
%	O
ammonium	O
sulphate	O
precipitation	O
followed	O
by	O
isolation	O
by	O
gel	O
filtration	O
chromatography	O
on	O
a	O
Superose	O
6	O
10	O
/	O
300	O
GL	O
column	O
equilibrated	O
with	O
10	O
mM	O
sodium	O
phosphate	O
(	O
pH	O
7	O
.	O
5	O
)	O
containing	O
0	O
.	O
1	O
M	O
NaCl	O
,	O
5	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
and	O
0	O
.	O
3	O
mM	O
sodium	O
azide	O
.	O

Concentrations	O
were	O
determined	O
spectrophotometrically	O
,	O
and	O
purity	O
was	O
checked	O
by	O
7	O
.	O
5	O
%	O
DS	O
-	O
PAGE	O
under	O
reducing	O
condition	O
.	O

Before	O
ELISA	O
experiments	O
,	O
spectrin	B-GP
was	O
extensively	O
dialyzed	O
against	O
5	O
mM	O
phosphate	O
to	O
remove	O
DTT	O
and	O
EDTA	O
.	O

Detection	O
of	O
anti	O
-	O
band	B-GP
3	I-GP
and	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP

For	O
detection	O
of	O
anti	O
-	O
band	B-GP
3	I-GP
and	O
anti	O
-	O
spectrin	B-GP
antibodies	B-GP
,	O
ELISA	O
was	O
carried	O
out	O
as	O
previously	O
described	O
with	O
some	O
modifications57	O
.	O

Briefly	O
,	O
plates	O
were	O
coated	O
overnight	O
at	O
4	O
ºC	O
with	O
5	O
ng	O
of	O
band	B-GP
3	I-GP
or	O
50	O
ng	O
of	O
spectrin	B-GP
,	O
blocked	O
with	O
3	O
%	O
BSA	B-GP
,	O
and	O
incubated	O
with	O
sera	O
samples	O
diluted	O
1	O
:	O
100	O
in	O
PBS	O
containing	O
1	O
%	O
BSA	B-GP
(	O
PBS	O
.	O
1	O
%	O
BSA	B-GP
)	O
for	O
2	O
h	O
at	O
37	O
ºC	O
.	O

Peroxidase	B-GP
conjugated	O
anti	O
-	O
human	B-OG
IgG	B-GP
at	O
a	O
dilution	O
of	O
1	O
:	O
1000	O
in	O
PBS	O
.	O
1	O
%	O
BSA	B-GP
was	O
added	O
and	O
the	O
plates	O
were	O
incubated	O
at	O
37	O
ºC	O
for	O
90	O
min	O
.	O

Wells	O
were	O
developed	O
with	O
O	O
-	O
phenylenediamine	O
substrate	O
(	O
benzene	O
-	O
1	O
,	O
2	O
-	O
diamine	O
).	O

Antibody	B-GP
values	O
were	O
expressed	O
as	O
reactivity	O
index	O
(	O
RI	O
),	O
which	O
was	O
calculated	O
as	O
the	O
ratio	O
between	O
the	O
mean	O
OD	O
generated	O
by	O
each	O
duplicate	O
and	O
the	O
mean	O
OD	O
plus	O
two	O
standard	O
deviations	O
of	O
samples	O
from	O
eight	O
healthy	O
blood	O
donors	O
never	O
exposed	O
to	O
malaria	B-DS
.	O

RIs	O
equal	O
or	O
greater	O
than	O
1	O
.	O
0	O
were	O
scored	O
as	O
positive	O
.	O

Bioinformatics	O
analyses	O

Mimicry	O
candidate	O
detection	O
analysis	O

To	O
identify	O
molecular	O
mimicry	O
candidate	O
proteins	O
between	O
the	O
entire	O
P	B-OG
.	I-OG
vivax	I-OG
proteome	O
and	O
human	B-OG
RBCs	O
,	O
we	O
used	O
a	O
modified	O
Perl	O
version	O
of	O
a	O
local	O
pipeline	O
created	O
by	O
Ludin	O
et	O
al	O
.	O
40	O
.	O

The	O
term	O
mimetic	O
is	O
refereed	O
here	O
as	O
the	O
display	O
of	O
any	O
parasite	O
protein	O
whose	O
primary	O
structure	O
resembles	O
primary	O
structures	O
of	O
the	O
host	O
and	O
possibly	O
confers	O
a	O
benefit	O
to	O
the	O
parasite	O
.	O

Ludin	O
´	O
s	O
pipeline	O
works	O
following	O
several	O
steps	O
.	O

First	O
,	O
a	O
blastp	O
search	O
against	O
free	O
-	O
living	O
eukaryotic	O
organisms	O
unrelated	O
to	O
pathogenicity	O
was	O
performed	O
to	O
eliminate	O
the	O
generally	O
conserved	O
proteins58	O
.	O

Then	O
,	O
specific	O
parasites	O
sequences	O
were	O
masked	O
for	O
possible	O
peptide	O
signal	O
sites	O
using	O
Phobius	O
software59	O
and	O
divided	O
into	O
14	O
length	O
size	O
overlapping	O
fragments	O
,	O
which	O
were	O
aligned	O
against	O
our	O
free	O
-	O
living	O
control	O
proteomes	O
to	O
remove	O
similar	O
peptides	O
.	O

Finally	O
,	O
these	O
14	O
-	O
mers	O
sequences	O
parasite	O
-	O
specific	O
were	O
compared	O
using	O
blast	O
alignment	O
against	O
the	O
RBC	O
human	B-OG
proteome	O
.	O

Only	O
the	O
high	O
-	O
scoring	O
segment	O
pairs	O
(	O
HSPs	O
),	O
e	O
-	O
value	O
≤	O
10	O
−	O
10	O
,	O
from	O
BLAST	O
were	O
selected	O
as	O
final	O
mimicry	O
candidates	O
.	O

Throughout	O
all	O
pipeline	O
,	O
redundancy	O
control	O
filters	O
steps	O
were	O
used	O
.	O

Comparison	O
between	O
P	B-OG
.	I-OG
falciparum	I-OG
and	O
P	B-OG
.	I-OG
vivax	I-OG
sequences	O
orthologous	O
to	O
spectrin	B-GP

We	O
searched	O
for	O
amino	O
acid	O
sequence	O
differences	O
that	O
could	O
help	O
to	O
identify	O
the	O
specific	O
aspects	O
that	O
make	O
P	B-OG
.	I-OG
vivax	I-OG
-	O
associated	O
anemia	B-DS
different	O
from	O
the	O
one	O
observed	O
for	O
P	B-OG
.	I-OG
falciparum	I-OG
.	O

We	O
aligned	O
P	B-OG
.	I-OG
vixax	I-OG
mimetic	O
protein	O
sequences	O
against	O
P	B-OG
.	I-OG
falciparum	I-OG
sequences	O
,	O
using	O
blastp	O
algorithm	O
.	O

To	O
evaluate	O
the	O
gene	O
disposition	O
over	O
the	O
genus	O
Plasmodium	B-OG
,	O
a	O
search	O
for	O
orthologous	O
sequences	O
was	O
done	O
between	O
all	O
available	O
Plasmodium	B-OG
species	O
in	O
PlasmoDB	O
version	O
2960	O
.	O

The	O
mimicry	O
amino	O
acid	O
sequences	O
were	O
submitted	O
to	O
the	O
OrthoMCL	O
program61	O
using	O
a	O
total	O
of	O
nine	O
isolates	O
from	O
different	O
Plasmodium	B-OG
species	O
:	O
P	B-OG
.	I-OG
falciparum	I-OG
3D7	I-OG
(	O
PF3D7_0206500	B-GP
).	O
P	B-OG
.	I-OG
berghei	I-OG
ANKA	I-OG
(	O
PBANKA_0304100	B-GP
),	O
P	B-OG
.	I-OG
yoelli	I-OG
yoelli	I-OG
17X	I-OG
(	O
PY17X_0304700	B-GP
),	O
P	B-OG
.	I-OG
yoelli	I-OG
yoelli	I-OG
YM	I-OG
(	O
PMY_0305000	B-GP
),	O
P	B-OG
.	I-OG
yoelli	I-OG
yoelli	I-OG
17XNL	I-OG
(	O
PY00070	B-GP
),	O
P	B-OG
.	I-OG
chabaudi	I-OG
chabaudi	I-OG
(	O
PCHAS_0306300	B-GP
),	O
P	B-OG
.	I-OG
knowlesi	I-OG
strain	I-OG
H	I-OG
(	O
PKNH_0414500	B-GP
),	O
P	B-OG
.	I-OG
vivax	I-OG
Sal	I-OG
-	I-OG
1	I-OG
(	O
PVX_003755	B-GP
)	O
and	O
P	B-OG
.	I-OG
cynomolgi	I-OG
strain	I-OG
B	I-OG
(	O
PCYB_042380	B-GP
),	O
which	O
were	O
publicly	O
available	O
at	O
this	O
time	O
.	O

The	O
recovered	O
sequences	O
were	O
subjected	O
to	O
a	O
maximum	O
likelihood	O
phylogenetic	O
analysis	O
using	O
PhyML62	O
and	O
visualized	O
using	O
Figtree	O
program	O
(	O
http	O
://	O
tree	O
.	O
bio	O
.	O
ed	O
.	O
ac	O
.	O
uk	O
/	O
software	O
/	O
figtree	O
/).	O

Data	O
Availability	O

All	O
data	O
generated	O
or	O
analysed	O
during	O
this	O
study	O
are	O
included	O
in	O
this	O
published	O
article	O
(	O
and	O
its	O
Supplementary	O
Information	O
files	O
).	O

Electronic	O
supplementary	O
material	O

Original	O
2D	O
-	O
SDS	O
-	O
PAGE	O
stained	O
with	O
colloidal	O
Coomassie	O
Blue	O
G	O
-	O
250	O
of	O
100	O
µg	O
of	O
RBC	O
protein	O
extract	O
using	O
7	O
cm	O
,	O
pH	O
4	O
-	O
7	O
IPG	O
strip	O
RBCs	O
immunoreactive	O
proteins	O
identified	O
by	O
peptide	O
mass	O
fingerprint	O
(	O
PMF	O
)	O
RBCs	O
immunoreactive	O
proteins	O
identified	O
by	O
MS	O
/	O
MS	O
peptide	O
fragmentation	O
or	O
by	O
de	O
novo	O
sequencing	O

Electronic	O
supplementary	O
material	O

Supplementary	O
information	O
accompanies	O
this	O
paper	O
at	O
10	O
.	O
1038	O
/	O
s41598	O
-	O
018	O
-	O
27109	O
-	O
6	O
.	O

Publisher	O
'	O
s	O
note	O
:	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

